Aim: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the standard treatment for patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCNHL). Nevertheless, anthracyclines are contraindicated for some patients, e.g. cardiac dysfunction, severe hepatic dysfunction, jaundice. Thus, this study assessed the effectiveness of non-anthracycline chemotherapy regimen cyclophosphamide, vincristine, and prednisone (CVP) in elderly DLBCNHL patients vs. the standard CHOP. Methods: This retrospective study included 418 DLBCNHL patients diagnosed between 2003 and 2006 and followed until March 2014. During this period of time, rituximab was not available for all patients, particularly for patients older than 60 years. Results: CHOP and CVP were administered to 351 (84%) and 67 (16%) patients, respectively. Older age and comorbidities, particularly cardiovascular and diabetes mellitus, were independent determinants for not receiving CHOP. Patients received more courses of CHOP treatment than that of CVP (6 vs. 3 courses; P < 0.001) and developed more toxicities (48.4% vs. 23.9%; P < 0.001), particularly fatigue, alopecia, and gastrointestinal tract toxicities. Complete response rate was higher in CHOP than in CVP (69.9% vs. 29.9%; P < 0.001). Moreover, early death was signifi cantly higher in CVP group of patients than in CHOP (43.3% vs. 8.6%; P < 0.001). After a median follow-up of 71 months, the median overall survival (OS) and event-free survival (EFS) were signifi cantly better in CHOP than in CVP (49.5 vs. 3.7 months and 32.2 vs. 3.5 months; P < 0.001 for both, respectively). Older age, poor age-adjusted International Prognostic Index scores, not receiving CHOP or consolidative radiotherapy were independent predictors of poor OS and EFS. Conclusion: Use of the CVP regime to treat DLBCNHL patients who were unfi t to the standard CHOP treatment was associated with lower remission rates and poorer EFS and OS in this group of patients.
Introduction
Non-Hodgkin's lymphoma (NHL) was the 10th most commonly diagnosed cancer and the 9th cause of cancer mortality in the world in 2012. [1] In Egypt, NHL was the 4th most common cancer in males and 5th in females and the 5th cause of cancer mortality. [1, 2] NHL is a diverse group of malignancies with different clinical and biological features. [3] Diffuse large B-cell NHL (DLBCNHL) is the most common NHL type in the world, accounting for 30% of NHL and 80% of its aggressive subtypes. [4] In Egypt, DLBCNHL accounts for 44.5% of lymphoid malignancies in a population-based cancer registry [5] and 50% of NHL subtypes at the Egyptian National Cancer Institute. [6] DLBCNHL treatment mostly relies on multi-agent combination chemotherapy. [7] The addition of the anti-CD20 monoclonal antibody rituximab to the chemotherapy combination dramatically improved overall survival (OS). [8, 9] Anthracyclines, particularly doxorubicin are an integral component of these combination chemotherapy regimens, e.g. cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP); procarbazine, methotrexate, doxorubicin, cyclophosphamide, etoposidecytarabine, bleomycin, vincristine, methotrexate; methotrexate-bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone; methotrexate, doxorubicin, cyclophosphamide, vincristine, dexamethasone, bleomycin, and many others. [10] Intensive chemotherapy with more agents failed to show additional benefi t, and the CHOP regimen was concluded to be the best available for patients with intermediate and high-grade NHL, including DLBCNHL. [7] Reductions in dose intensity clearly determine treatment effi cacy. [11] However, patients with older age, comorbidities, particularly cardiovascular, and expected higher morbidity and mortality may hinder the use of an anthracycline. [12, 13] Compared to
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anthracycline-containing regimens, the 3-year OS is almost halved when a non-anthracycline-containing regimen is used with an absolute survival reduction of 23%. [12] Thus, the aim of this retrospective study was to investigate the effectiveness of non-anthracycline chemotherapy regimen on elderly DLBCNHL patients by mainly focusing on geriatric organ dysfunction, frailty and comorbidities vs. suboptimal treatment with the cyclophosphamide, vincristine, and prednisone (CVP) vs. the standard CHOP to assess the factors that impact the regimen choice. intravenous (IV) on day 1, doxorubicin 50 mg/m 2 IV on day 1, vincristine 1.4 mg/m 2 (maximum 2 mg) IV on day 1 and prednisone 100 mg p.o. for 5 days) or CVP regimen (same as CHOP without doxorubicin) and followed-up until March 2014 via phone conversation. Response to therapy was assessed using the response criteria developed by the lymphoma International Working Group. [14] OS is calculated from the date of diagnosis to the date of death from any cause or last follow-up. Event-free survival (EFS) was calculated from the date of starting treatment to the date of relapse, progression, death or last follows up. [14] Clinicopathological data were extracted from patients' medical records. This study was approved by the Institutional Review Board of the Egyptian National Cancer Institute.
Methods

Study population
Statistical analyses
Statistical analyses were performed using IBM SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA). Nominal and categorical variables were compared using the Chi-square or Fisher's exact test. Numerical variables were compared using t-test or Man-Whitney's test. Multivariate logistic regression was used to describe the use of CHOP or CVP, controlling for patient covariates. Unadjusted survival was estimated using the Kaplan-Meier method and groups were compared using the log-rank test. Stepwise Cox regression hazards model was used for calculating adjusted survival for each treatment, controlling for patients covariates. A probability P ≤ 0.05 was considered statistically signifi cant. The primary endpoint was OS. The secondary endpoint included EFS, complete response (CR) rate, and treatment-related toxicities.
Results
Patients' characteristics
CHOP and CVP were administered to 351 (84%) and 67 (16%) patients, respectively. Compared with those receiving CVP, patients receiving CHOP were signifi cantly younger, having less comorbidity, better performance status (PS), fewer B-symptoms, and lower International Prognostic Index-risk (IPI-risk) categories [ Table 1 ]. Logistic regression analysis assessed the impact of different baseline characteristics on the likelihood to receive CHOP or CVP. Only age and comorbidities were independent determinants of the regimen received [ Table 2 ]. Older patients had 10.5 odds of not receiving CHOP compared to the younger patients (95% confi dence interval (CI): 4.6-23.6; P < 0.001). Patients with comorbidities had 37.2 odds of not receiving CHOP compared to those with no comorbidities (95% CI: 12.6-109.6; P < 0.001). Patients with diabetes mellitus, hypertension, and cardiovascular diseases (e.g. myocardial infarction, heart failure, cerebrovascular stroke) were signifi cantly more common in the CVP group [ Table 3 ]. Among different comorbidities, cardiovascular diseases, and diabetes mellitus were the most signifi cant ones that guided regimen selection. The odds of not receiving CHOP were 125 times higher in patients with cardiovascular diseases compared to those without cardiovascular diseases (95% CI: 48-327; P < 0.001). The odds of not receiving CHOP was 9 times higher in patients with diabetes mellitus compared to those without diabetes mellitus (95% CI: 3-28; P < 0.001).
Treatment responses and toxicities
Patients with CHOP treatment received more chemotherapy cycles than those treated with CVP (median 6 and 3 cycles, respectively; P < 0.001; Table 4 ). CR rate was higher in CHOP-treated patients than in CVP-treated patients (69.9% vs. 29.9%; P < 0.001). More patients received radiotherapy after CHOP treatment achieved CR than CVP-treated patients (22.2% vs. 3%; P = 0.001; Table 3 ). Compared to CVP, CHOP was associated with signifi cantly higher toxicities (48.4% vs. 23.9%; P < 0.001), particularly fatigue, alopecia, and gastrointestinal tract toxicities. However, early deaths following one or two chemotherapy courses were signifi cantly higher in patients with CVP treatment than with CHOP treatment (43.3% vs. 8.6%; P < 0.001).
Overall survival and event-free survival
The median EFS was 22 months (range: 1.0-104.7 months; 95% CI: 16.7-27.4 months) in these patients [ Figure 1 ]. The 2-and 5-year EFS rates were 47.8% and 30.4%, respectively. However, compared to CVP, CHOP was associated with signifi cantly better EFS (median of 32.2 vs. 3.5 months; P < 0.001). After 5 years, no CVP-treated patients were event-free compared to 36% of CHOP-treated patients [ Table 5 ]. The EFS was also signifi cantly better in patients who were younger than 60 years, females had no comorbidities or B symptoms, good PS, lower stages, or lower IPI scores or those who received consolidative radiotherapy. Multivariate analysis showed that age > 60 years old, poor age-adjusted IPI (aaIPI) scores, and not receiving CHOP or radiotherapy were independent predictors for poor EFS [ Table 6 ].
The median follow-up period of time was 71 months (range between 1.0 and 111.7 months; Figure 1 ]. At the last follow-up, 263 patients were deceased (199 in the CHOP group and 64 in the CVP group). The median OS rate was 28.6 (95% CI: 17.0-40.2) for this cohort of patients. However, the median OS rate was signifi cantly longer in CHOP-treated patients than that of CVP-treated patients (49.5 vs. 3.7 months; P < 0.001; Table 5 ). The median OS rate was also signifi cantly longer in young patients without comorbidities, bulky disease or B symptoms, good PS, lower stages, and IPI or aaIPI scores or patients who received consolidation radiotherapy. The multivariate analysis showed that age > 60 years, poor aaIPI scores, and not receiving CHOP or radiotherapy were independent predictors of poor OS [ Table 6 ].
Discussion
Since its development in the late 1960's, doxorubicin has been fi rmly established as the most effective single agent in the treatment of malignant lymphoma. [15, 16] The CHOP regime was invented in the late 1970's and after its effi cacy in NHL was established, it became the standard of care as it produced high CR rate and durable effects. [15, 17] Its known adverse effects mainly affect the cardiovascular system. [15, 16, 18] Reduction of inter-treatment intervals (CHOP-14) and the addition of rituximab (R-CHOP) were shown to improve treatment outcomes. [16] CHOP-14 does not appear to be superior to CHOP-21 when given with rituximab, but associates with increased toxicities, including an increased risk of Pneumocystis Jiroveci Pneumonia. Use of R-CHOP-21 is recommended rather than R-CHOP-14. This is primarily due to decreased need for growth factor support, and a lack of data showing the superiority of one regimen over another in the rituximab era. More intensive chemotherapy or additional agents have failed to show additional benefi t. [7] However, elimination of anthracycline from the treatment regimen reduced the CR rate, duration of response and disease stabilization, and OS. [12, 13] In the current study, 16% of DLBCNHL patients (67/418) did not receive anthracycline, whereas other studies showed a higher percentage (20-67%) as they only included patients aged 66 years or older. [12, 19, 20] However, Link et al. [18] reported a lower percentage in an older population. Different studies in the different period of time and inclusion criteria may explain this variance. The rate of anthracycline use in the treatment of DLBCNHL did not vary with time, that is, between the pre-rituximab era and the post-rituximab era. [18] Furthermore, similar to other studies, [18, 19, 21] our current study showed that older age and comorbidities were strong indictors of treatment regimen selection without doxorubicin in addition to cardiovascular diseases and diabetes mellitus but the lower relevance of kidney and liver disease. [19] Pre-therapy heart disease, diabetes, hypertension, and older age were reported to be independent predictors of cardiotoxicity and subsequent death from the same cause. [22] [23] [24] Our results also concur with those of van de Schans et al. [25] and Peters et al. [26] regarding the impact of poor PS and estimated short survival on the likelihood of treatment regimens without anthracycline. We showed that early death, that is, following 1-2 chemotherapy courses was encountered more in the non-anthracycline group (43.3% vs. 8.6%). Expected higher toxicities are another important reason. While this is diffi cult to assess quantitatively before therapy is given, it was confi rmed by the higher rates of toxicities in the CHOP compared to the CVP group (48.4% vs. 23.9%).
The lower response rate with the CVP regimen without anthracycline than anthracycline-containing CHOP regimen confi rms the established fact that anthracycline is the most active single agent in the treatment of lymphoma. [12, 13, 15, 16] In the current study, doxorubicin contributed almost 40% of the CRs exceeding the [27] Our current study clearly shows that patients are failing to achieve CR only had a median OS of 4.4 months compared to 76.8 months in those who achieved CR with almost 11-fold higher relative risk of death. CHOP-produced CR rates is comparable to those reported by Khaled et al., [28] Burton et al., [29] Hallack Neto et al. [30] [ Table 7 ]. However, a large Egyptian study by Abdelhamid et al. [6] reported a 10% higher CR rate. This latter study only included younger patients with a maximum age of 60, better PS, and lower aaIPI scores. In contrast, our current [6, 31] In the current study, remo val of the anthracycline doxorubicin from the CHOP regimen signifi cantly reduced the median OS ( unadjusted from 49.5 to 3.7 months, i.e. 45.8 months and adjusted from 44 to 9 months, i.e. 35 months) and the 3-ye ar OS (unadjusted from 54.5% to 3.9% i.e. 50.5% and adjusted from 52% to 19% i.e. 33%) with an increase in the hazards of death by 4 times. This is similar to Tien et al. [12] and Link et al. [18] who show ed a 22% and 16% decline in 3-year OS, respectively [ Table 7 ]. The difference in our study (33%) may be due to the poorer outcome of patients receiving non-anthracycline-containing regimens (19%) compared to that in the mentioned studies (29% and 33%). This may be due to the more developed health care system in the US than Egypt as the former ranks 37th and the latter ranks 63th in overall health system performance. [33] A high performing health care system is capable of providing better supportive therapies for patients that are elderly, having comorbidities and progressing on inadequate anti-lymphoma therapy.
OS with CHOP treatment (52% at 3 years) in the current study is comparable to the 49-57% fi gure reported by many authors [ Table 7 ], [6, 9, 12, 18] but was lower than the 60-70% OS reported by Habermann et al., [32] Burton et al., [29] and Khaled et al. [28] All of these studies performed prospective trials where patients were carefully selected and generally fi t to tolerate therapy. It is understandable that results from phase III studies do not always translate into corresponding outcomes in the general population. [18] Similar to CR and OS, our current data showed that removal of doxorubicin from the CHOP regimen signifi cantly reduced EFS. We could not easily fi nd information on the use of CVP in DLBCNHL to compare our EFS with the studies that comparison of anthracycline-containing regimens to non-anthracycline-containing regimens only showed OS. [12, 18] The EFS rate of CHOP treatment in our current study is similar to Sehn et al. [9] and Habermann et al. [32] However, it was lower than that of Khaled et al. [28] and Burton et al. [29] This may be explained by the difference in study settings between the well-controlled environment of a clinical trial and the community practice environment. The dis ease-free survival of our study (75.9% at 2 years) was similar to that of Abdelhamid et al. [6] (68.8%) who used a similar setting to our study. It was higher than that reported by Hallack Neto et al. [30] This retrospective Brazilian study reported on a relatively small number of DLBCNHL is potentially curable after treated with anthracycline-containing regimens; however, a signifi cant proportion of patients do not receive anthracyclines, particularly doxorubicin for various reasons, e.g. older age, expected poor tolerance or signifi cant comorbidities. These patients present an unmet medical need. [12] Measures that may decrease toxicity and improve anthracycline tolerance includes adequate supports (e.g. hematopoietic growth factors), dose reductions, increase in infusion time, the addition of cardio-protectants (e.g. dexrazoxane). [16, 18, 26, 34, 35] An alternative less-toxic and more tolerable anthracycline may be considered if feasible, e.g. liposomal doxorubicin, [36, 37] epirubicin, [38] mitoxantrone [39] or pixantrone. [40] In case an anthracycline cannot be used, substitution with other agents, e.g. etoposide or gemcitabine may better than omission. [41] Addition of the immunotherapy agent like rituximab to non-anthracycline-containing regimens signifi cantly improves the outcomes and should be considered. [18] Non-anthracycline-containing regimens with the addition of rituximab produced equivalent outcomes to anthracycline-containing regimens. [12, 18, 19] 
